The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions : A Spanish Multicentre Retrospective Study Efectividad de guselkumab en pacientes con hidradenitis supurativa en condiciones de práctica clínica: estudio retrospectivo y multicéntrico en España
Rivera, Raquel (Hospital 12 de Octubre (Madrid))
Pozo, Tomás (Hospital Río Hortega)
Alfageme Roldan, Fernando (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Díaz Ley, Blanca (Hospital Universitario del Sureste (Arganda))
Osorio, Guiovana Fernandad (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Chico, Ricardo (Hospital Infanta Sofía. Alcobendas)
Vilarrasa-Rull, Eva (Institut d'Investigació Biomèdica Sant Pau)
Silvente, Catiana (Hospital Universitario Infanta Leonor)
Ciudad Blanco, Cristina (Hospital General Universitario Gregorio Marañón)
Romaní, J. (Hospital General de Granollers)
Martorell, Antonio (Hospital de Manises (València))
Fernández, P. (Hospital Universitario Ramón y Cajal (Madrid))
Romero Ferreiro, Carmen (Universidad Francisco de Vitoria (Pozuelo de Alarcón))
Molina Leyva, Alejandro (European Hidradenitis Suppurativa Foundation (EHSF))
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	Hidradenitis suppurativa (HS) is a chronic skin condition causing lesions in which high levels of interleukin (IL)-23 and T-helper 17 cells are found. Adalimumab remains the only approved treatment. Guselkumab, an antibody targeting the p19 protein subunit of extracellular IL-23, is approved for the treatment of moderate-severe psoriasis, but evidence on its efficacy in treating HS is limited. Objectives: To assess the effectiveness and safety of guselkumab in treating moderate-severe HS under clinical practice conditions. A multicentre retrospective observational study was carried out in 13 Spanish Hospitals including adult HS patients treated with guselkumab within a compassionate use programme (March 2020-March 2022). Data referred to patient demographic and clinical characteristics at treatment initiation (baseline), patient-reported outcomes (Numerical Pain Rating Scale [NPRS] and Dermatology Life Quality Index [DLQI]), physician scores (International Hidradenitis Suppurativa Severity Score System [IHS4], HS Physical Global Score [HS-PGA] and Hidradenitis Suppurativa Clinical Response [HiSCR]) were recorded at baseline and at 16, 24, and 48 weeks of treatment. A total of 69 patients were included. Most (84. 10%) had severe HS (Hurley III) and had been diagnosed for over ten years (58. 80%). The patients had been subjected to multiple non-biological (mean 3. 56) or biological (mean 1. 78) therapies, and almost 90% of those treated with biologics had received adalimumab. A significant decrease in IHS4, HS-PGA, NPRS, and DLQI scores was observed from baseline to 48 weeks of guselkumab treatment (all p < 0. 01). HiSCR was achieved in 58. 33% and 56. 52% of the patients at 16 and 24 weeks, respectively. Overall, 16 patients discontinued treatment, mostly due to inefficacy (n = 7) or loss of efficacy (n = 3). No serious adverse events were observed. Our results indicate that guselkumab may be a safe and effective therapeutic alternative for patients with severe HS that fail to respond to other biologics.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Castellà
Documento:	Article ; recerca ; Versió publicada
Materia:	Biologics ; Biológicos ; Evidencia del mundo real ; Guselkumab ; Hidradenitis suppurativa ; Hidradenitis supurativa ; Real-world evidence
Publicado en:	Actas dermo-sifiliográficas, Vol. 114 Núm. 9 (octubre 2023) , p. 755-762, ISSN 1578-2190

DOI: 10.1016/j.ad.2023.06.013
PMID: 37479135

8 p, 650.7 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados